PE20230412A1 - Compuestos para su uso en afecciones inflamatorias - Google Patents
Compuestos para su uso en afecciones inflamatoriasInfo
- Publication number
- PE20230412A1 PE20230412A1 PE2022001880A PE2022001880A PE20230412A1 PE 20230412 A1 PE20230412 A1 PE 20230412A1 PE 2022001880 A PE2022001880 A PE 2022001880A PE 2022001880 A PE2022001880 A PE 2022001880A PE 20230412 A1 PE20230412 A1 PE 20230412A1
- Authority
- PE
- Peru
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- independently selected
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000004968 inflammatory condition Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 241000689227 Cora <basidiomycete fungus> Species 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Referido a un compuesto de formula I, en donde X es O o NH; Y es CO o -COCH(CH3)CO-; cada n y p se selecciona independientemente entre 0 y 1; y q es 0, 1 o 2; cada R1, R3, R5, R9, R11 y R15 se selecciona independientemente entre H, alquilo C1-C6 sustituido o sin sustituir; entre otros; R2 es H, CORa, COORa, entre otros; cada R4, R8, R10, R12 y R16 se selecciona independientemente entre H y alquilo C1-C6 sustituido o sin sustituir; cada R7 y R13 es independientemente H, alquilo C1-C6 sustituido o sin sustituir, entre otros; R6 y R14 se selecciona independientemente entre H y alquilo C1-C6 sustituido o sin sustituir, entre otros; R17 es H, CORa, COORa, CONHRb, entre otros. En donde estos compuestos activan de receptores de tipo Toll. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto, una sal o estereoisomero del mismo y un portador farmaceuticamente aceptable, la fabricacion de un medicamento que contiene dicho compuesto para el tratamiento de la inflamacion, tales como la inflamacion inducida por patogenos o infeccion virica.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382152 | 2020-03-02 | ||
| EP20382192 | 2020-03-13 | ||
| EP20382266 | 2020-04-02 | ||
| EP20382339 | 2020-04-27 | ||
| EP20382815 | 2020-09-16 | ||
| EP20382816 | 2020-09-16 | ||
| EP21382059 | 2021-01-25 | ||
| PCT/EP2021/055187 WO2021175857A1 (en) | 2020-03-02 | 2021-03-02 | Compounds for use in inflammatory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230412A1 true PE20230412A1 (es) | 2023-03-07 |
Family
ID=74732953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001880A PE20230412A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en afecciones inflamatorias |
| PE2022001795A PE20230606A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en infecciones viricas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001795A PE20230606A1 (es) | 2020-03-02 | 2021-03-02 | Compuestos para su uso en infecciones viricas |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20230159594A1 (es) |
| EP (2) | EP4114435A1 (es) |
| JP (2) | JP2023517535A (es) |
| KR (2) | KR20220150350A (es) |
| CN (2) | CN115666616A (es) |
| AU (2) | AU2021231197A1 (es) |
| BR (2) | BR112022016675A2 (es) |
| CA (2) | CA3169540A1 (es) |
| CL (2) | CL2022002396A1 (es) |
| CO (2) | CO2022014031A2 (es) |
| IL (2) | IL296069A (es) |
| MX (2) | MX2022010926A (es) |
| PE (2) | PE20230412A1 (es) |
| TW (1) | TW202144381A (es) |
| UY (2) | UY39109A (es) |
| WO (2) | WO2021175831A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021232534A1 (en) * | 2020-03-02 | 2022-10-06 | Pharma Mar, S.A. | Compounds for use in the treatment of coronavirus infection |
| US20230159594A1 (en) * | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in viral infections |
| CN115243703A (zh) * | 2020-03-02 | 2022-10-25 | 法马马有限公司 | 用于组合治疗冠状病毒的pld |
| WO2024165764A1 (en) * | 2023-02-10 | 2024-08-15 | Pharma Mar, S.A. | Plitidepsin for use in the treatment of non-integrated dna viral infections |
| CN117285611B (zh) * | 2023-11-24 | 2024-02-09 | 中国海洋大学 | 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8922026D0 (en) * | 1989-09-29 | 1989-11-15 | Pharma Mar Sa | Novel anti-viral and cytotoxic agent |
| US6156724A (en) * | 1996-06-07 | 2000-12-05 | Rinehart; Kenneth L. | Uses of didemnins as immunomodulating agents |
| GB9803448D0 (en) | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
| HUP0101716A3 (en) * | 1998-04-14 | 2003-01-28 | Jomaa Hassan | Use of organo phosphonic and phosphinic acid derivatives for producing medicaments useful for therapeutic and preventative treatment of infections |
| DE60123232T2 (de) | 2000-04-07 | 2007-11-08 | Trustees Of The University Of Pennsylvania | Tamandarin und didemnin analoga und methoden zu deren herstellung und verwendung |
| UA76718C2 (uk) | 2000-06-30 | 2006-09-15 | Фарма Мар, С.А. | Протипухлинні похідні аплідину |
| CA2430897C (en) * | 2000-12-07 | 2010-11-16 | Universiteit Utrecht Holding B.V. | Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders |
| KR20050105477A (ko) * | 2003-02-21 | 2005-11-04 | 썬 파마슈티컬 인더스트리스 리미티드 | 안정한 안약 조성물 |
| MXPA05010064A (es) | 2003-03-21 | 2006-05-17 | Madeleine M Joullie | Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos. |
| WO2011020913A2 (en) | 2009-08-21 | 2011-02-24 | Pharma Mar, S.A. | Cyclodepsipeptide antiviral compounds |
| CN102762206A (zh) * | 2009-12-15 | 2012-10-31 | 诺华有限公司 | 免疫增强化合物的均匀悬液及其用途 |
| US20120040033A1 (en) * | 2010-08-10 | 2012-02-16 | Ernest Timothy Armstrong | Anti-infective mangrove extract against viruses, bacteria and fungi |
| GB201316524D0 (en) * | 2013-09-17 | 2013-10-30 | Medical Res Council | Biomarkers |
| EP3193875B1 (en) * | 2014-09-15 | 2022-02-16 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| JP2020524144A (ja) * | 2017-06-16 | 2020-08-13 | ヴァンダービルト ユニヴァーシティ | 微生物性炎症を処置するための方法および組成物 |
| US20230159594A1 (en) * | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in viral infections |
-
2021
- 2021-03-02 US US17/908,533 patent/US20230159594A1/en active Pending
- 2021-03-02 JP JP2022552937A patent/JP2023517535A/ja active Pending
- 2021-03-02 CN CN202180018734.0A patent/CN115666616A/zh active Pending
- 2021-03-02 US US17/908,526 patent/US20230295236A1/en active Pending
- 2021-03-02 MX MX2022010926A patent/MX2022010926A/es unknown
- 2021-03-02 PE PE2022001880A patent/PE20230412A1/es unknown
- 2021-03-02 JP JP2022552946A patent/JP2023517536A/ja active Pending
- 2021-03-02 KR KR1020227034280A patent/KR20220150350A/ko active Pending
- 2021-03-02 CA CA3169540A patent/CA3169540A1/en active Pending
- 2021-03-02 PE PE2022001795A patent/PE20230606A1/es unknown
- 2021-03-02 MX MX2022010921A patent/MX2022010921A/es unknown
- 2021-03-02 UY UY0001039109A patent/UY39109A/es unknown
- 2021-03-02 CA CA3169544A patent/CA3169544A1/en active Pending
- 2021-03-02 BR BR112022016675A patent/BR112022016675A2/pt unknown
- 2021-03-02 WO PCT/EP2021/055147 patent/WO2021175831A2/en not_active Ceased
- 2021-03-02 BR BR112022016604A patent/BR112022016604A2/pt unknown
- 2021-03-02 UY UY0001039110A patent/UY39110A/es unknown
- 2021-03-02 EP EP21708237.9A patent/EP4114435A1/en active Pending
- 2021-03-02 EP EP21708019.1A patent/EP4114433A2/en active Pending
- 2021-03-02 CN CN202180018363.6A patent/CN115461067A/zh active Pending
- 2021-03-02 AU AU2021231197A patent/AU2021231197A1/en active Pending
- 2021-03-02 TW TW110107292A patent/TW202144381A/zh unknown
- 2021-03-02 IL IL296069A patent/IL296069A/en unknown
- 2021-03-02 KR KR1020227034317A patent/KR20220151643A/ko active Pending
- 2021-03-02 WO PCT/EP2021/055187 patent/WO2021175857A1/en not_active Ceased
- 2021-03-02 AU AU2021232535A patent/AU2021232535A1/en active Pending
- 2021-03-02 IL IL296068A patent/IL296068A/en unknown
-
2022
- 2022-09-02 CL CL2022002396A patent/CL2022002396A1/es unknown
- 2022-09-02 CL CL2022002395A patent/CL2022002395A1/es unknown
- 2022-09-30 CO CONC2022/0014031A patent/CO2022014031A2/es unknown
- 2022-09-30 CO CONC2022/0014093A patent/CO2022014093A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022002396A1 (es) | 2023-06-30 |
| CO2022014031A2 (es) | 2022-10-21 |
| PE20230606A1 (es) | 2023-04-10 |
| IL296068A (en) | 2022-11-01 |
| EP4114435A1 (en) | 2023-01-11 |
| CA3169540A1 (en) | 2021-09-10 |
| CL2022002395A1 (es) | 2023-06-30 |
| BR112022016604A2 (pt) | 2022-10-11 |
| UY39110A (es) | 2021-09-30 |
| CN115666616A (zh) | 2023-01-31 |
| US20230295236A1 (en) | 2023-09-21 |
| AU2021231197A1 (en) | 2022-10-06 |
| EP4114433A2 (en) | 2023-01-11 |
| UY39109A (es) | 2021-09-30 |
| WO2021175857A1 (en) | 2021-09-10 |
| WO2021175831A2 (en) | 2021-09-10 |
| US20230159594A1 (en) | 2023-05-25 |
| BR112022016675A2 (pt) | 2022-10-11 |
| JP2023517535A (ja) | 2023-04-26 |
| MX2022010921A (es) | 2022-09-29 |
| KR20220151643A (ko) | 2022-11-15 |
| MX2022010926A (es) | 2022-09-29 |
| TW202144381A (zh) | 2021-12-01 |
| KR20220150350A (ko) | 2022-11-10 |
| TW202146038A (zh) | 2021-12-16 |
| WO2021175831A3 (en) | 2021-10-14 |
| CA3169544A1 (en) | 2021-09-10 |
| IL296069A (en) | 2022-11-01 |
| JP2023517536A (ja) | 2023-04-26 |
| AU2021232535A1 (en) | 2022-10-06 |
| CO2022014093A2 (es) | 2022-11-18 |
| CN115461067A (zh) | 2022-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230412A1 (es) | Compuestos para su uso en afecciones inflamatorias | |
| PE20250071A1 (es) | Compuesto ciclico que contiene accion inhibidora selectiva en kras por sobre hras y nras | |
| AR114290A1 (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| AR126076A1 (es) | Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| AR069490A1 (es) | Agonistas de los receptores de glucocorticoides | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR064874A1 (es) | Derivados de hexahidro y tetrahidropterinas,composiciones farmaceuticas que los contienen y usos de las mismas en trastornos cardiovasculares y psiquiatricos entre otros | |
| AR030243A1 (es) | Carboxamidas heterociclicas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento antiviral y metodo in vitro para inhibir el adn polimerasa viral | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| RU2010116253A (ru) | Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила | |
| PE20201256A1 (es) | Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas | |
| AR042635A1 (es) | Imidazoquinolinas arilsustituidas y composiciones farmaceuticas que las contienen | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR072610A1 (es) | Composiciones para el tratamiento del dolor y/o la inflamacion | |
| PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR082633A1 (es) | Analogos de tetraciclina | |
| AR068466A1 (es) | Cianoisoquinolina | |
| AR039562A1 (es) | Compuestos oxo-azabiciclicos | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| CO6430439A2 (es) | Agonistas del receptor de esfingosina -1- fosfato | |
| AR062405A1 (es) | Derivados de isoindol | |
| PE20220704A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos |